Arabi, Yaseen M <br/><br/>
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.  [electronic resource] 

 -  Trials  Jan 2020 
 - 8 p.  digital 
<br/><br/> Publication Type: Clinical Trial Protocol; Journal Article 
<br/><br/><label>ISSN: </label>1745-6215 
<br/><br/><label>Standard No.: </label>10.1186/s13063-019-3846-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--adverse effects<br/>Coronavirus Infections--diagnosis<br/>Data Interpretation, Statistical<br/>Double-Blind Method<br/>Drug Combinations<br/>Host-Pathogen Interactions<br/>Humans<br/>Interferon beta-1b--adverse effects<br/>Lopinavir--adverse effects<br/>Middle East Respiratory Syndrome Coronavirus--drug effects<br/>Multicenter Studies as Topic<br/>Randomized Controlled Trials as Topic<br/>Ritonavir--adverse effects<br/>Saudi Arabia<br/>Time Factors<br/>Treatment Outcome